FGFR2 and cholangiocarcinoma: In addition to pemigatinib and futibatinib, infigratinib is one of the most clinically advanced and investigated FGFR inhibitors in CCA management as they have promising clinical activity in previously treated patients with locally advanced or metastatic CCA with known FGFR2 gene fusions or rearrangements.